Transcript Healthcare associated pneumonia.
Healthcare Associated Pneumonia
Barbara G. Bielska, M.D.
Clarian Arnett Health Infectious Diseases Department
Definitions
HCAP-signs, symptoms and radiographic presence of PNA in CAP patients with recent contact with the healthcare system HAP- 48-72 hrs after hospital admission VAP- 48-72 hrs after endotracheal intubation
Epidemiology of Pneumonia
Leading cause of infectious diseases related death globally and in the US CDC (2006) more than 56 K deaths 1.2 mln out of 35 mln annual US hospitalizations US expenditures > $8 billion annually 300K cases of HAP/y with associated mortality rate 30-70% HAP lengthens hospital stay by 7-9 days
Healthcare Associated Pneumonia ATS/IDSA Guidelines 2005
Hospitalization for 2 days or more in the preceding 90 days Residence in the NH or ECF Home infusion therapy ( including abx) Chronic dialysis within 30 days Home wound care Family member with a MDR pathogen
HCAP as clinical entity
Large, heterogeneous patient population with a poorly defined conglomeration of risk factors that may increase the risk of infection with a drug resistant pathogen
HCAP Definitions by Study
Kollef at al 2005 ( hospitalization in 30 d, transfer from other facility, chronic HD) Carratala at al 2007 (hospitalization in 90 d, NH /ECF residence, home infusions/IV therapy, attended hospital/HD clinic past 30 d, IV chemotherapy past 30 d) Shorr at al 2008 (hospitalization in past 90 d, NH/ECF, chronic dialysis, immunocompromised state)
HACP Definitions by Study
Venditti at al 2009 ( hospitalization/surgery in the past 180 d, NH/ECF, attended hospital/HD clinic in the past 30 d, IV chemotherapy in the past 30 d) Shindo at al 2009 ( hospitalization in past 90 d, NH/ECF, home infusions/ IV therapy, chronic dialysis, home wound care,
The Magnitude of the HCAP Population CAP vs. HCAP by study Kollef ’05- CAP-69.2%, HCAP-30.8% Micek ‘’07 and Shorr’ 08- CAP-32.6%, HCAP- 67.4% Carratala ’07- CAP-82.7%, HCAP- 17.3% Venditti’ 09- CAP- 71.2%, HCAP-28.8% Shindo ’09- CAP- 62%, HCAP- 38% Avarage CAP-63.9%, HCAP- 36.5% % HCAP of community dwelling adults hospitalized for pneumonia
Etiology and Outcomes HCAP vs. CAP
Micek at al ’07single center retrospective cohort analysis ( US) 2003-05 HCAP (n- 431), CAP (n-208) S.aureus (% MRSA) 44.5% (68.8), 25.5% (47.1) S.pneumoniae 10.4%, 40.9% P.aeruginosa 25.5% , 4.8% H. influenzae 4.2%, 17.3% Legionella sp. 0.2%, 3.4% HLS not provided, In hospital mortality 24.6% VS. 9.1%
Etiology and Outcomes HCAP vs. CAP
Venditti at al ’09 multicenter prospective observational study ( Italy, 55 hosp. ’07) HCAP (n-90), CAP (n-49) Variable no pathogen data HLS in days, mean 18.7 vs. 14.7 , p-value<0.05
In hospital mortality 17.8% vs. 6.7%, p-value <0.05
Etiology and Outcomes HCAP vs. CAP
Shindo at al ’09 single center retrospective observational study (Japan), 2005-07 HCAP (n-141), CAP (n-230) Pathogen (%, culture positive) S. pneumoniae -13.5, 19.1
S.aureus (% MRSA)- 9.9 (35.7), 6.1 (14.3) Pseudomonas sp.-5.7, 1.7
No pathogen identified- 45.4, 52.6
Previous abx past 90 d (%)-63.1, 20.9
In hospital mortality %- 21.3, 7.4
HCAP or Drug Resistant PNA
Variables independently associated with resistant pathogen : MRSA, P.aeruginosa, ESBL Klebsiella sp /other non fermenting GNR’s, Recent hospitalization, 3 mo Nursing Home residence/ LTCF, poor functional state Long term hemodialysis ICU admission Broad spectrum antibiotics use, 3 mo
Patient’s Risk for Resistant Pathogen
Knowledge of reason for prior admission Duration of prior hospitalization Receipt of antibiotic therapy Known MDR pathogen circulating in community or hospital Immunosuppressive disease present or therapy given Search for drug resistant pathogen specific risk factor is complicated by study’s statistical power, selection bias, limitations of case control study design Limited evidence for community dwellers
HCAP, HAP, VAP Diagnosis Difficult, no reliable tools to determine if patient has PNA No reliable methods to determine causative pathogen when PNA present Sampling methods for ventilator-associated pneumonia: Validation using different histologic and microbiological references. Crit Care Med. 28: 2000; 2799-2804. New infiltrate on CXR, fever, purulent sputum other signs of clinical deterioration Clinical method was shown to be specific for HAP in only 27 of 84 patients in a series reported by Fagon at al.
Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients. Chest. 103: 1993; 547-553
Conditions mimicking PNA in critically ill Congestive heart failure Pulmonary embolism Atelectasis Acute respiratory distress syndrome (ARDS) Pulmonary hemorrhage Drug reactions
Imperfect diagnostic tests
Blood cultures, limited role, sensitivity is only 8% to 20% Sputum neither sensitive, nor specific Tracheo-bronchial aspirates- high sensitivity, weakness- does not differentiate between pathogen and colonizer Hospital-acquired pneumonia: Risk factors, microbiology, and treatment. Chest. 119: 2001; 373S-384S.
BAL, PSB’s do not differ from less invasive tests in terms of sensitivity, specificity or, more importantly, morbidity and mortality luck of consensus on the role of invasive diagnostic testing for HAP, subject of ongoing debate Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: Evaluation of outcome. Am J Respir Crit Care Med. 162: 2000; 119-125. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: A randomized trial. Ann Intern Med. 132: 2000; 621-630.
HCAP, HAP, VAP Treatment Delay in empiric antibiotics use, worse outcome International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest. 120: 2001; 955-970. Mortality with prompt abx use 30% vs. 91 % when delayed Nosocomial pneumonia: A multivariate analysis of risk and prognosis. Chest. 93: 1988; 318-324 Regimens in patients with no known risk factors for MDR pathogens, and who have early-onset pneumonia (within 5 days of hospitalization) should include coverage for Enterobacter spp., E. coli, Klebsiella spp., Proteus spp., and Serratia marcescens), Haemophilus influenzae and Streptococcus pneumoniae, MSS. aureus
HCAP, HAP, VAP Treatment
ceftriaxone or a quinolone (e.g., ciprofloxacin or levofloxacin) or ampicillin-sulbactam or eratpenem
fluoroquinolone in the empirical regimen of patients with penicillin allergies
penicillin skin testing – a mean to decrease fluoroquinolones use
A pilot study of penicillin skin testing in patients with a history of penicillin allergy admitted to a medical ICU. Chest. 118: 2000; 1106-1108.
Ceftazidime
Antibiotics for Empirical Therapy of Hospital-Acquired Pneumonia * in Patients at Risk for Multidrug-Resistant Pathogens Antibiotic Adult Dosage †
Antipseudomonal cephalosporin Cefepime 1-2 g every 8-12 hr 2 g every 8 hr Carbepenems Imipenem 500 mg every 6 hr or 1 g every 8 hr Meropenem 1 g every 8 hr Beta-lactam–beta-lactamase inhibitor Piperacillin-tazobactam 4.5 g every 6 hr Aminoglycosides Gentamicin 7 mg/kg/day Tobramycin Levofloxacin 7 mg/kg/day Amikacin 20 mg/kg/day Antipseudomonal quinolones 750 mg/day Ciprofloxacin 400 mg every 8 hr Vancomycin 15 mg/kg every 12 hr Linezolid 600 mg every 12 hr Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
Duration of treatment
No consensus, initial low suspicion, no change in clinical status- dc in 72 hrs
prescription. Am J Respir Crit Care Med. 162: 2000; 505-511. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic
Guided by severity, time to clinical response, and the pathogenic organism
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare associated pneumonia. Am J Respir Crit Care Med. 171: 2005; 388-416.
Treat for at least 72 hours after a clinical response is achieved
International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest. 120: 2001; 955-970.
Recommendations for Assessing Response to Treatment
-Modifications of empirical therapy should be based on results of microbiology testing in conjunction with clinical parameters. -Clinical improvement of HCAP usually takes 2 to 3 days and therefore therapy should not be changed during this period unless there is a rapid clinical decline.
-Narrowing therapy to the most focused regimen possible on the basis of culture data (de escalation of antimicrobials) should be considered for the responding patient. -The nonresponding patient should be evaluated for possible MDR pathogens, extrapulmonary sites of infection, complications of pneumonia and its therapy, and mimics of pneumonia. -Testing should be directed to whichever of these causes is likely after physical examination of the patient.
Prevention Measures Based on expert opinion rather than hard data CDC published a set of 74 recommendations for preventing NAP , only 15 strongly supported by well-designed experimental or epidemiologic studies 14 out of those 15 dealt with surveillance, education, hand washing, sterilization, proper use of gloves, value of vaccination, and sanitation Prophylactic antibiotics not be used routinely , only one supported by well-designed studies Centers for Disease Control and Prevention. Guidelines for prevention of nosocomial pneumonia. MMWR Morb Mortal Wkly Rep. 46: 1997; 1-79.
Prevention Measures Proper hand washing, use of gloves, and measures to reduce contamination from respiratory therapy equipment Universally recognized, often not performed, see observational study performed in an ICU setting 10% of health care workers washed their hands before having direct patient contact and only 32% washed their hands after patient contact Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest. 115: 1999; 1378-1382.
Reduction of HCAP Incidence Reduce immunosuppression, reduce sedation, avoid transportation of patients out of the ICU, and provide adequate nutrition Oral placement of endotracheal or gastric tubes (sinusitis reduction) Subglottic secretion drainage, continuous suction of oropharyngeal secretions in an effort to prevent pooling and thus aspiration Semirecumbent position prevents aspiration of refluxed gastric contents Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: A randomised trial. Lancet. 354: 1999; 1851-1858.
Reduction of HCAP Incidence Administration of prophylactic antibiotics or nonabsorbable antibiotics for the purpose of gastrointestinal decontamination Not shown to influence mortality or length of stay, use of antibiotics in this manner may lead to the development of resistant organisms International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest. 120: 2001; 955-970. Results regarding the role of histamine blockers in the development of HAP are conflicting Antibiotics select out resistant or virulent organisms, 65% of PNA in vented patients who received prophylactic abx was caused by Acinetobacter and /or Pseudomonas sp.
In antibiotic-naïve patients, only 19% of infections were caused by these pathogens Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis. 139: 1989; 877-884.
Things to Remember
HACP, HAP, VAP = BAD for the patient Quantitative diagnostic microbiology- controversial!
Cover likely bugs promptly Know your local bugs De-escalate, shorten duration of therapy Specific regimen, combination therapy- no proven benefits
Things to Do
Get patient’s HOB at 30-45 degrees Get the ET tube out Get the NG tube out Get of the ventilator as ap